Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers

International Journal of Infectious Diseases

Volumn 33, Issue , 2015, Pages 97-103

  Zeng, Huihui ^a   Cai, Haodong ^a   Wang, Ying ^b   Shen, Ying ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Children; Chronic hepatitis B; Development; Growth; Mothers; Telbivudine

Indexed keywords

HEPATITIS B VACCINE; TELBIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; THYMIDINE;

ADULT; ANKYLOGLOSSIA; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BOY; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHRONIC HEPATITIS; CONGENITAL DEAFNESS; CONGENITAL HEART DISEASE; CONGENITAL HIP DISLOCATION; CONGENITAL HYPOTHYROIDISM; CONGENITAL MALFORMATION; CONGENITAL SKIN DISEASE; CONTROLLED STUDY; DEVELOPMENTAL QUOTIENT; FEMALE; FIRST TRIMESTER PREGNANCY; GIRL; HEART MUSCLE INJURY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOCALCEMIA; INFANT; INFANT DISEASE; INFANTILE DIARRHEA; INGUINAL HERNIA; LANGUAGE DELAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; NEWBORN INFECTION; NOSE OBSTRUCTION; NUCHAL CORD; OUTCOME ASSESSMENT; PHENYLKETONURIA; PNEUMONIA; PRENATAL DRUG EXPOSURE; RESPIRATORY TRACT INFECTION; SKIN HEMANGIOMA; THIRD TRIMESTER PREGNANCY; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; BODY WEIGHT; CHINA; DELIVERY; FETOMATERNAL TRANSFUSION; HEPATITIS B, CHRONIC; MOUTH ABNORMALITIES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE; PREVENTION AND CONTROL; REFERENCE VALUE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BODY MASS INDEX; BODY WEIGHT; CHILD DEVELOPMENT; CHINA; DELIVERY, OBSTETRIC; FEMALE; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MATERNAL-FETAL EXCHANGE; MOUTH ABNORMALITIES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; REFERENCE VALUES; THYMIDINE;

EID: 84921981058     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.09.002     Document Type: Article

References (28)

1. Makuwa M., Caron M., Souquière S., Malonga-Mouelet G., Mahé A., Kazanji M. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol 2008, 46:754-756.
2. Liu C.Y., Chang N.T., Chou P. Seroprevalence of HBV in immigrant pregnant women and coverage of HBIG vaccine for neonates born to chronically infected immigrant mothers in Hsin-Chu County, Taiwan. Vaccine 2007, 25:7706-7710.
3. Lin C.C., Hsieh H.S., Huang Y.J., Huang Y.L., Ku M.K., Hung H.C. Hepatitis B virus infection among pregnant women in Taiwan: comparison between women born in Taiwan and other southeast countries. BMC Public Health 2008, 8:49.
4. Jonas M.M. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009, 29(Suppl 1):133-139.
5. Leung N. Chronic hepatitis B in Asian women of childbearing age. Hepatol Int 2009, 3(Suppl 1):24-31.
6. Shen Q. One pregnant woman withdrew from lamivudine therapy and died of severe chronic hepatitis B. Strait Pharm J 2005, 17:182-183.
7. Zhang L., Gui X., Wang B., Ji H., Yisilafu R., Li F., et al. A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission. Gastroenterology 2012, 142:773-781.
8. Wong F., Pai R., Van Schalkwyk J., Yoshida E.M. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Ann Hepatol 2014, 13:187-195.
9. Lu Y.P., Liang X.J., Xiao X.M., Huang S.M., Liu Z.W., Li J., et al. LdT during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. Clin Lab 2014, 60:571-586.
10. Han L., Zhang H.W., Xie J.X., Zhang Q., Wang H.Y., Cao G.W. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011, 17:4321-4333.
11. But D.Y., Yuen M.F., Fung J., Lai C.L. Safety evaluation of telbivudine. Expert Opin Drug Saf 2010, 9:821-829.
12. Han G.R., Cao M.K., Zhao W., Jiang H.X., Wang C.M., Bai S.F., et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011, 55:1215-1221.
13. Pan C.Q., Han G.R., Jiang H.X., Zhao W., Cao M.K., Wang C.M., et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012, 10:520-526.
14. Liu M., Cai H., Yi W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat 2013, 20(Suppl 1):65-70.
15. Deng M., Zhou X., Gao S., Yang S.G., Wang B., Chen H.Z., et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 2012, 9:185.
16. Zhang L.J., Wang L. Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2009, 17:561-563.
17. WHO child growth standards based on length/height, weight and age. Acta Paediatr Suppl 2006, 450:76-85. WHO Multicentre Growth Reference Study Group.
18. Safir A., Levy A., Sikuler E., Sheiner E. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 2010, 30:765-770.
19. Tse K.Y., Ho L.F., Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005, 43:771-775.
20. Su G.G., Pan K.H., Zhao N.F., Fang S.H., Yang D.H., Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004, 10:910-912.
21. Wiseman E., Fraser M.A., Holden S., Glass A., Kidson B.L., Heron L.G., et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009, 190:489-492.
22. Li Y., Qiu X.J., Ceng X. Chinese meta analysis of risk factors for birth defects. Modern Preventive Medicine 2007, 34:2073-2075.
23. Hosseini M., Navidi I., Hesamifard B., Yousefifard M., Jafari N., Poorchaloo S.R., et al. Weight, height and body mass index nomograms: early adiposity rebound in a sample of children in Tehran, Iran. Int J Prev Med 2013, 4:1414-1420.
24. He H., Chen X.X., Meng J., Li Y.C., Pan Y., Wang Y. Survey on the current situation of growth and development of children under 7 years old in Beijing. Chinese Journal of Child Health Care 2011, 19:531-534.
25. Han S., Liang D., Zhang Y., Shi X.J., Wang F.Z., Liu W., et al. Impact of intrauterine low-level lead exposure on growth and neurobehavioral development in neonates. Chinese Journal of Public Health 2013, 29:1283-1285.
26. Qi X.J., Zheng M.L., Wu C.H., Chang X.L., Wang G.Q., Lu D.S., Zhou Z.J. Impact of prenatal pyrethroid exposure on neurodevelopment of one-year old infants. J Hygiene Res 2011, 40:693-697.
27. Liu X., Qiu W., Liang X., Feng J., Huang S., Zhang H., et al. The study of women during pregnancy and/or lactation received anti-thyroid treatment: effects on the offspring's thyroid function, physical and intellectual development. Journal Guide of China Medicine 2014, 12:6-8.
28. Li B.F., Zheng L.Y., Hou D. The influencing factors of infant early intelligence development. Journal of Chinese Practical Gynecology and Obstetrics 2013, 20:504-506.